Clozapine Information

Clozapine is the only medication approved by the U.S. Food and Drug Administration (FDA) for managing treatment-resistant schizophrenia and for reducing the risk of recurrent suicidal behavior in patients with schizophrenia or schizoffective disorder.

Despite its known benefits, prescribers are opting to trial non–evidence-based treatments before clozapine. These delays reduce the likelihood of a superior response to clozapine. 

Unfortunately, clinicians’ perceptions of clozapine and lack of familiarity with initiation and management limit the use of this life-changing treatment. (Leung, 2025)​

​More recently a Finnish study published in the Lancet showed reduced second-episode psychosis, reduced rehospitalization and overall improved 10 year outcomes in people experiencing first-episode psychosis  who were started on clozapine earlier. 

"This marks an important time to bring forth a call to action for increased use of clozapine." (Leung, 2025)

Check out the resources below for more information.